Norway
Calluna Pharma, founded in 2024, is a clinical-stage biotech company based in Norway. The company focuses on developing first-in-class therapies to address chronic inflammation and fibrosis by targeting the upstream amplifiers of diseases. This innovative approach could potentially yield treatments applicable to numerous therapeutic areas, especially where existing options fall short.
Their commitment to advancing the field is reflected in their use of immunology to push boundaries and develop treatments that can significantly improve patient outcomes. Operating within the Biotechnology and Pharmaceutical industries, Calluna Pharma aspires to challenge the status quo with real-world solutions for serious diseases.
The company recently secured a €75.00M Series A investment on 01 January 2024, with substantial backing from prominent investors including Forbion, Investinor, Sarsia, and NVEST VENTURE. This funding underscores strong investor confidence in their cutting-edge therapeutic approach and potential market impact.
